Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Completed 4Recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 8

Sponsor

Conditions

Myasthenia Gravis 8

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × zilucoplan × Clear all
NCT06055959 2026-05-08

ziMyG

UCB Pharma

Phase 2/3 Recruiting
8 enrolled

Myasthenia Gravis

NCT06435312 2026-05-08

ziMyG+

UCB Pharma

Phase 3 Enrolling by invitation
8 enrolled

Myasthenia Gravis

NCT04225871 2026-04-24

RAISE-XT

UCB Pharma

Phase 3 Active not recruiting
200 enrolled

Myasthenia Gravis

NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
31 enrolled 11 charts

Myasthenia Gravis

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Ohio State University

Phase 3 Recruiting
15 enrolled

Myasthenia Gravis

NCT05514873 2025-09-03

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

UCB Pharma

Phase 3 Completed
26 enrolled 14 charts

Myasthenia Gravis

NCT04115293 2025-07-16

RAISE

UCB Pharma

Phase 3 Completed
174 enrolled 19 charts

Myasthenia Gravis

NCT03315130 2022-07-27

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

UCB Pharma

Phase 2 Completed
45 enrolled 21 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡